Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 1 ROP; defined as:~   * Zone I, any stage ROP with plus disease, or~  * Zone I, stage 3 ROP without plus disease, or~  * Zone II, stage 2 or 3 ROP with plus disease~2. No previous treatment for ROP in the study eye; no previous bevacizumab treatment in the non-study eye~Exclusion Criteria:~The following exclusions apply to the study eye:~1. Nasolacrimal duct obstruction~2. Major ocular anomalies (e.g., cataract, coloboma)~3. Any opacity that precludes an adequate view of the retina~If purulent ocular discharge is present in either eye, then the infant is ineligible.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Bevacizumab 0.250 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.125 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.063 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.031 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.016 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.008 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.004 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.002 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied

Based on this trial design, predict the completion outcome and termination type (if applicable).